Kodiak Sciences (NASDAQ:KOD) Shares Climb 6.5% – What’s Next?

Posted by Stanley Muller on Oct 21st, 2026

Kodiak Sciences Inc. (NASDAQ:KOD – Get Free Report) shares were up 6.5% on Monday. The stock traded as high as $91.23 and last traded at $91.31. 357,764 shares traded hands during mid-day trading, a decline of 69% from the average session volume of 1,142,722 shares. The stock had previously closed at $85.75.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on KOD. Jefferies Financial Group reaffirmed a “buy” rating and issued a $112.00 target price on shares of Kodiak Sciences in a research note on Monday, September 28th. The Goldman Sachs Group reissued a “neutral” rating and set a $103.00 price target on shares of Kodiak Sciences in a research note on Wednesday, September 30th. JPMorgan Chase & Co. increased their price target on shares of Kodiak Sciences from $56.00 to $66.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. UBS Group boosted their price objective on shares of Kodiak Sciences from $80.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, September 28th. Finally, HC Wainwright upped their price objective on Kodiak Sciences from $96.00 to $126.00 and gave the stock a “buy” rating in a report on Monday, October 12th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Kodiak Sciences currently has an average rating of “Moderate Buy” and an average price target of $104.71.

Check Out Our Latest Stock Analysis on Kodiak Sciences

Kodiak Sciences Stock Up 1.8%

The firm has a fifty day moving average of $55.38 and a 200-day moving average of $45.10. The firm has a market cap of $5.84 billion, a P/E ratio of -22.19 and a beta of 2.03.

Kodiak Sciences (NASDAQ:KOD – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.09). Sell-side analysts anticipate that Kodiak Sciences Inc. will post -3.97 EPS for the current year.

Insider Activity

In other Kodiak Sciences news, Director Bros. Advisors Lp Baker purchased 807,840 shares of the stock in a transaction dated Monday, September 28th. The stock was bought at an average price of $72.57 per share, for a total transaction of $58,624,948.80. Following the transaction, the director directly owned 19,121,134 shares in the company, valued at $1,387,620,694.38. This represents a 4.41% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Over the last 90 days, insiders have bought 1,941,755 shares of company stock valued at $156,986,026. 44.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kodiak Sciences

Institutional investors and hedge funds have recently modified their holdings of the business. Abel Hall LLC bought a new position in shares of Kodiak Sciences in the 3rd quarter worth $423,000. JGP Global Gestao de Recursos Ltda. bought a new stake in Kodiak Sciences in the third quarter valued at about $347,000. Engineers Gate Manager LP increased its holdings in Kodiak Sciences by 145.8% in the second quarter. Engineers Gate Manager LP now owns 29,537 shares of the company’s stock valued at $1,151,000 after purchasing an additional 17,520 shares during the last quarter. Squarepoint Ops LLC increased its holdings in Kodiak Sciences by 112.6% in the second quarter. Squarepoint Ops LLC now owns 151,098 shares of the company’s stock valued at $5,887,000 after purchasing an additional 80,042 shares during the last quarter. Finally, Arizona State Retirement System lifted its stake in Kodiak Sciences by 6.9% in the second quarter. Arizona State Retirement System now owns 8,533 shares of the company’s stock valued at $332,000 after buying an additional 554 shares during the period. 89.06% of the stock is owned by institutional investors.

About Kodiak Sciences

(Get Free Report)

Kodiak Sciences Inc (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. The company’s research centers on therapies designed to address conditions that can cause vision loss, including diabetic macular edema, neovascular age-related macular degeneration and retinal vein occlusion.

Kodiak’s proprietary Antibody Biopolymer Conjugate platform is designed to combine the targeting capabilities of antibody-based medicines with a biodegradable polymer intended to extend the duration of treatment in the eye.